TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20131246

Group type: EXPERIMENTAL
Intervention: Rituximab (1,000 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 19115423

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) plus taper
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Group support (GS) plus taper
Number of subjects: 86

Group type: COMPARATOR
Intervention: Treatment as usual (taper only) plus physician counselling
Number of subjects: 86
Study: 15828586

Group type: EXPERIMENTAL
Intervention: Dihydroartemisin
Number of subjects: 165

Group type: COMPARATOR
Intervention: Quinine
Number of subjects: 165

Group type: COMPARATOR
Intervention: Sulfadoxin-pyrimethamin
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Dihydroartemisin (second cure)
Number of subjects: 165
Study: 12597653

Group type: EXPERIMENTAL
Intervention: Bifenthrin 100 mg/m2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bifenthrin 200 mg/m2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bifenthrin 50 mg/m2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bifenthrin 25 mg/m2
Number of subjects: 5

Group type: COMPARATOR
Intervention: Malathion 2 g/m2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bifenthrin 25 mg/m2 and 50 mg/m2
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Overall efficacy of bifenthrin
Number of subjects: 5
Study: 10469685

Group type: EXPERIMENTAL
Intervention: FSH-HP
Number of subjects: 31

Group type: COMPARATOR
Intervention: FSH-HP + rhLH
Number of subjects: 31
Study: 8737435

Group type: EXPERIMENTAL
Intervention: In-service training programme for medical assistants
Number of subjects: 0
Study: 1906808

Group type: EXPERIMENTAL
Intervention: Bromocriptine monotherapy
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Bromocriptine with levodopa (combination therapy)
Number of subjects: 702

Group type: COMPARATOR
Intervention: Levodopa (control group)
Number of subjects: 702
Study: 6352661

Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cefazolin/Tobramycin
Number of subjects: 50
Study: 27241348

Group type: EXPERIMENTAL
Intervention: Family Implemented TEACCH for Toddlers (FITT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Community services as usual
Number of subjects: 50
Study: 28281050

Group type: EXPERIMENTAL
Intervention: Risk model-guided (RMG) antiemetic prophylaxis
Number of subjects: 324

Group type: COMPARATOR
Intervention: Physician's choice (PC) antiemetic prophylaxis
Number of subjects: 324
Study: 27164480

Group type: EXPERIMENTAL
Intervention: GAME (Goals - Activity - Motor Enrichment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 30
Study: 24948586

Group type: EXPERIMENTAL
Intervention: High-dose melphalan 200 mg/m(2) plus salvage ASCT
Number of subjects: 174

Group type: COMPARATOR
Intervention: Oral cyclophosphamide (400mg/m(2) per week for 12 weeks)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: PAD induction therapy
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Salvage ASCT
Number of subjects: 174

Group type: COMPARATOR
Intervention: Cyclophosphamide
Number of subjects: 174
Study: 22101219

Group type: EXPERIMENTAL
Intervention: Study agent
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 19730965

Group type: EXPERIMENTAL
Intervention: Applied Tension (AT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: No Applied Tension (Control)
Number of subjects: 98
Study: 17404152

Group type: EXPERIMENTAL
Intervention: GIP (gemcitibine + ifosfamide + cisplatin)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Paclitaxel (225 mg/m(2) over 3 h every 3 weeks)
Number of subjects: 485
Study: 14660219

Group type: COMPARATOR
Intervention: Shorts (S)
Number of subjects: 24
Study: 11176403

Group type: EXPERIMENTAL
Intervention: Intravesical electromotive oxybutynin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravesical passive diffusion oxybutynin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral oxybutynin
Number of subjects: 10
Study: 9572635

Group type: EXPERIMENTAL
Intervention: High doses of prednisolone for the first six months, followed by lower doses thereafter
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Low dose glucocorticoid schedule after initial high doses
Number of subjects: 24
Study: 8046559

Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol mouthrinse
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: 0.2% delmopinol mouthrinse
Number of subjects: 133

Group type: COMPARATOR
Intervention: Vehicle control mouthrinse
Number of subjects: 133
Study: 2657953

Group type: EXPERIMENTAL
Intervention: Paraghurt tablets (freeze‐dried culture of Streptococcus faecium)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 31003114

Group type: EXPERIMENTAL
Intervention: Guided internet-based self-help intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 110
Study: 28801112

Group type: EXPERIMENTAL
Intervention: Coracoclavicular ligament reconstruction using autologous gracilis tendon with suture anchor
Number of subjects: 42

Group type: COMPARATOR
Intervention: Clavicular hook plate
Number of subjects: 42
Study: 25193602

Group type: EXPERIMENTAL
Intervention: Peer counseling intervention (contacted by telephone or in clinic up to 4 months post-delivery)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Peer counseling intervention
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (negative attitudes)
Number of subjects: 120
Study: 22406043

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.2 ng/mL
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Sufentanil 0.3 ng/mL
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sufentanil 0.4 ng/mL
Number of subjects: 48
Study: 21271601

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 18652265

Group type: COMPARATOR
Intervention: Clearfil SE Bond (SE, Kuraray) applied to dentin surfaces prepared with 600-grit SiC abrasive paper
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-speed tungsten carbide bur with Clearfil SE Bond (SE, Kuraray)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High-speed diamond bur with Clearfil S3 Bond (S3, Kuraray)
Number of subjects: 50
Study: 17063980

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg (Merck S.A. Indústrias Químicas)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Movatec 15 mg (control formulation)
Number of subjects: 24
Study: 14670782

Group type: EXPERIMENTAL
Intervention: Dexamethasone as adjuvant therapy
Number of subjects: 598

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 598
Study: 10966840

Group type: EXPERIMENTAL
Intervention: 1000 mg FCHG49 glucosamine HCl, 800 mg TRH122 low molecular weight sodium chondroitin sulfate and 152 mg manganese ascorbate twice daily (Cosamin DS)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 8867164

Group type: EXPERIMENTAL
Intervention: Topical anesthesia
Number of subjects: 27

Group type: COMPARATOR
Intervention: Peribulbar injection
Number of subjects: 27
Study: 1460202

Group type: EXPERIMENTAL
Intervention: Greer Pen (GP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Greer DermaPIK (DP)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Center Multi‐Test (MT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Morrow Brown needle (MB)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glycerosaline control
Number of subjects: 20
Study: 6422735

Group type: EXPERIMENTAL
Intervention: Propranolol plus lidoflazine (L)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Propranolol plus placebo (P)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Propranolol plus lidoflazine (L) after crossover
Number of subjects: 29

Group type: COMPARATOR
Intervention: Propranolol plus placebo (P) after crossover
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Combined therapy (Propranolol + Lidoflazine)
Number of subjects: 29
Study: 29234941

Group type: EXPERIMENTAL
Intervention: Laparoscopic group (LAG)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Open group
Number of subjects: 322
Study: 26916239

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (Ctrl)
Number of subjects: 16
Study: 25803256

Group type: EXPERIMENTAL
Intervention: Flexible regimen of daily risedronate (5 mg)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Fixed regimen of daily risedronate (5 mg)
Number of subjects: 448
Study: 23899372

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Captopril
Number of subjects: 0
Study: 20811320

Group type: EXPERIMENTAL
Intervention: FK778
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (reduction of immunosuppression)
Number of subjects: 0
Study: 18240234

Group type: EXPERIMENTAL
Intervention: Corticosteroids (CS) alone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Oral azathioprine (AZA)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Intravenous pulse cyclophosphamide (CYC)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 72

Group type: COMPARATOR
Intervention: Low-dose corticosteroids (CS) therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Corticosteroid-related adverse events
Number of subjects: 72
Study: 16376467

Group type: EXPERIMENTAL
Intervention: Men during hip lateral rotation
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Hip lateral rotation test
Number of subjects: 46
Study: 12745095

Group type: EXPERIMENTAL
Intervention: Theophylline (200 mg IV)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 100
Study: 10855739

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8-16 mg once daily
Number of subjects: 4964

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4964
Study: 9357355

Group type: EXPERIMENTAL
Intervention: Two-step intervention (physician letter and peer counseling call)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 460
Study: 8403634

Group type: EXPERIMENTAL
Intervention: Septopal beads
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Systemic antibiotics and/or gentamicin (Septopal) antibiotic beads
Number of subjects: 35
Study: 3941533

Group type: EXPERIMENTAL
Intervention: Mailed continuing education program on hypertension
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no mailed education)
Number of subjects: 0
Study: 31428854

Group type: EXPERIMENTAL
Intervention: G+1.50 (additional 1500 mL of water)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: G+2.25 (additional 2250 mL of water)
Number of subjects: 115

Group type: COMPARATOR
Intervention: CON (no additional water)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: G+0.50 (additional 500 mL of water)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: G+1.00 (additional 1000 mL of water)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: G+1.50 and G+2.25
Number of subjects: 115
Study: 30191972

Group type: EXPERIMENTAL
Intervention: Avatrombopag (20 mg/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 26811524

Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin (GO)
Number of subjects: 237

Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 237
Study: 24908236

Group type: EXPERIMENTAL
Intervention: Regular aerobic exercise (30 min, 3 times a week for 3 months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (healthy lean women, no intervention)
Number of subjects: 15
Study: 24205150

Group type: EXPERIMENTAL
Intervention: Nurse home visits during pregnancy and until the child's second birthday
Number of subjects: 460

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 460
Study: 21165734

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl infusion
Number of subjects: 60
Study: 18312772

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg/day)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 17000891

Group type: EXPERIMENTAL
Intervention: Abciximab (n=15)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Eptifibatide (n=14)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH; 70 U/kg bolus)
Number of subjects: 29
Study: 14531242

Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 2.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nebulized levalbuterol 1.25 mg
Number of subjects: 20
Study: 10763958

Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg p.o., b.i.d. for 1 month)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo (for 1 month)
Number of subjects: 16
Study: 8881614

Group type: EXPERIMENTAL
Intervention: 0.25% hyperbaric bupivacaine (3.2‐3.6 ml, 8‐9 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% hyperbaric bupivacaine (3.6‐4.0 ml, 9‐10 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.25% hyperbaric bupivacaine (4.0‐4.4 ml, 10‐11 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (3.2‐3.6 ml, 8‐9 mg)
Number of subjects: 60
Study: 1357550

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micrograms, twice daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3082733

Group type: EXPERIMENTAL
Intervention: Supplementary parenteral nutrition (200 mg nitrogen per kg per day via central catheter)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Oral diet (40 kcal per kg per day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Supplementary parenteral nutrition
Number of subjects: 40
Study: 29135458

Group type: EXPERIMENTAL
Intervention: HVLA manipulation (MT group)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CCF exercise protocol (CCF group)
Number of subjects: 25
Study: 27153085

Group type: EXPERIMENTAL
Intervention: Partial meal replacement program with app support
Number of subjects: 146
Study: 25436614

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ) and Artemether-lumefantrine (AL)
Number of subjects: 413
Study: 22584529

Group type: EXPERIMENTAL
Intervention: Silver lipidocolloid dressing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20446755

Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonists (LTRAs)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Long-acting beta2 agonists
Number of subjects: 361
Study: 18593773

Group type: EXPERIMENTAL
Intervention: Growth hormone replacement therapy in group A (22 patients)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (35 healthy men)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Standard replacement therapy without GH in group B (13 patients)
Number of subjects: 35
Study: 18830566

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg IV on admission, followed by 20 mg orally for 7 days
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (no gastric acid inhibitor)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Omeprazole group
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 237
Study: 15866357

Group type: EXPERIMENTAL
Intervention: Acetazolamide (AA)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 11177112

Group type: EXPERIMENTAL
Intervention: Biperiden hydrochloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pirenzepine hydrochloride
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Air (as placebo)
Number of subjects: 12
Study: 9757147

Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole twice a day plus 1.0 mg alprazolam
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole twice a day plus 0.25 mg triazolam
Number of subjects: 5

Group type: COMPARATOR
Intervention: ketoconazole placebo plus 1.0 mg alprazolam
Number of subjects: 5

Group type: COMPARATOR
Intervention: ketoconazole placebo plus 0.25 mg triazolam
Number of subjects: 5
Study: 7923801

Group type: EXPERIMENTAL
Intervention: Naproxene Sodium (550 mg) 30 minutes before surgery
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63

Group type: COMPARATOR
Intervention: No drug
Number of subjects: 63
Study: 3410590

Group type: EXPERIMENTAL
Intervention: Methyclothiazide (M)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Combination of Methyclothiazide with Triamterene (25, 50, 75 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 31927021

Group type: EXPERIMENTAL
Intervention: Video conveying university commitment to cultural diversity and inclusion (n = 45)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control video depicting a campus tour (n = 39)
Number of subjects: 84
Study: 31466930

Group type: EXPERIMENTAL
Intervention: Passive Self‐ligating brackets: Smart Clip (3M Unitek)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Active Self‐ligating brackets: Empower AO (American Orthodontics)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional brackets (3M Unitek)
Number of subjects: 42
Study: 28985308

Group type: EXPERIMENTAL
Intervention: STOP Diabetes education programme (multi-component lifestyle behaviour change intervention)
Number of subjects: 0
Study: 26182440

Group type: EXPERIMENTAL
Intervention: NaHCO3 + CAF
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: All experimental conditions
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rating of perceived exertion
Number of subjects: 10
Study: 27129013

Group type: EXPERIMENTAL
Intervention: AZD3839 (1-300 mg single oral doses)
Number of subjects: 54
Study: 22390677

Group type: EXPERIMENTAL
Intervention: Bacopa monnieri (CDRI08 300 mg/day)
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Pycnogenol (150 mg/day)
Number of subjects: 465

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 465
Study: 19351782

Group type: EXPERIMENTAL
Intervention: Nicotrol nasal spray (actual and expected doses varied)
Number of subjects: 48

Group type: COMPARATOR
Intervention: No-spray control
Number of subjects: 48
Study: 17314698

Group type: EXPERIMENTAL
Intervention: Diet with eight graded intakes of phenylalanine without tyrosine
Number of subjects: 5
Study: 16278986

Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil (125 mg capsules, twice a day for 10 days)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 12133084

Group type: EXPERIMENTAL
Intervention: Oral diazepam 10 mg (n=56)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo (n=56)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 112
Study: 10101984

Group type: EXPERIMENTAL
Intervention: Two-hour physician workshop followed by information provided before each visit on patient expectations, illness worry, and DSM-IV disorders.
Number of subjects: 500
Study: 7771834

Group type: EXPERIMENTAL
Intervention: Oral vitamin E for 4 weeks, vitamin C and allopurinol 2 days before and 1 day after coronary artery bypass grafting (Group 1)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Vitamin E given only 2 days before the operation, vitamin C and allopurinol (Group 3)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (Group 4)
Number of subjects: 81
Study: 2335704

Group type: EXPERIMENTAL
Intervention: nonpreserved drops
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10 different drops
Number of subjects: 45
Study: 387216

Group type: EXPERIMENTAL
Intervention: Concurrent combination therapy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Single-drug chemotherapy administered sequentially
Number of subjects: 121
Study: 29790122

Group type: EXPERIMENTAL
Intervention: Modulating circle providing information about onset, offset, and acoustic amplitude envelope of speech
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 28557552

Group type: EXPERIMENTAL
Intervention: Family discord present
Number of subjects: 610
Study: 27333830

Group type: EXPERIMENTAL
Intervention: BNG-1
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: BNG-1 and Placebo
Number of subjects: 42
Study: 23374147

Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia with Target-Controlled Infusion (TIVA-TCI)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Balanced Inhalation Anesthesia (BAL)
Number of subjects: 28
Study: 19939864

Group type: EXPERIMENTAL
Intervention: Flumazenil plus gabapentin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19095858

Group type: EXPERIMENTAL
Intervention: CSE (intrathecal bupivacaine 2.5 mg with fentanyl 25 microg)
Number of subjects: 100

Group type: COMPARATOR
Intervention: EPID (epidural bupivacaine 2.5 mg/mL, 3 mL, followed by bupivacaine 1.25 mg/mL, 10 mL with fentanyl 50 microg)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CSE
Number of subjects: 100

Group type: COMPARATOR
Intervention: EPID
Number of subjects: 100
Study: 18075414

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy (early static images)
Number of subjects: 100
Study: 15154290

Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study: 11134829

Group type: EXPERIMENTAL
Intervention: Paracetamol (20 mg/kg rectally)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Reference group (n=66) with uncomplicated pregnancy and delivery in vertex position without vacuum extraction
Number of subjects: 61